No evidence of exogenous origin for the abnormal glutathione redox state in schizophrenia
Introduction
Schizophrenia has been associated with increased oxidative stress (Do et al., 2009, Kano et al., 2012). In aerobic cells, reactive oxygen species (ROS) and free radicals are byproducts of oxidative metabolism. The defense against oxidative stress is complex, involving multiple enzymes and antioxidant compounds. One of the major mechanisms for sequestration of ROS and free radicals is through the glutathione pathway where the reduced form of glutathione (monomeric glutathione or GSH) is converted to its oxidized form (glutathione disulfide or GSSG). Glutathione is present mainly (~ 99%) in GSH form in the body (Lenton et al., 1999). Although there are multiple defense systems and several of them have shown to be abnormal in schizophrenia, low GSH concentration is perhaps among the most consistently reported in schizophrenia. Low GSH has been found in post-mortem brain samples (Yao et al., 2006, Gawryluk et al., 2011) and in-vivo magnetic resonance spectroscopy studies (Do et al., 2000, Wood et al., 2009). GSH levels were decreased in the blood of antipsychotics-free and antipsychotics-treated patients (Raffa et al., 2009) and in cerebrospinal fluid of drug-naive patients (Do et al., 2000) suggesting that it is not secondary to antipsychotics. Taken together, low GSH level in schizophrenia provides a good index of an abnormal redox state associated with this illness, which is relatively consistently observed and not attributed solely to treatment with antipsychotics. Administration of the glutathione precursor n-acetylcysteine (NAC) improved clinical symptoms in patients (Berk et al., 2008), further supporting the association of oxidative stress with schizophrenia. However, it is unclear whether the mechanism that produces such effects is a direct result of pathophysiology associated with schizophrenia, an indirect result of other related pathology, or arising from sources outside the primary disease process that may differ between patients and controls. Hence, we examined the potential role of three exogenous factors in mediating oxidative stress, as indexed by abnormal GSH and GSSG levels, in schizophrenia: diet, smoking and antipsychotics.
First, diet is an important source of variance in oxidative stress in the general population (Jenkinson et al., 1999, Watson et al., 2005). We assessed whether there is a deficit in intake of antioxidants in food in schizophrenia, as dietary antioxidant contents provide the substrate and also regulate enzymes in the redox pathways (Bagchi et al., 1997, Huber et al., 2002). One prior study found no evidence of reduced antioxidant intake in schizophrenia (Strassnig et al., 2005). Another study showed that lower plasma antioxidant levels were not correlated with body mass (Reddy et al., 2003). However, to date no study has assessed whether dietary antioxidant intake affects the reported glutathione deficit in schizophrenia.
Second, smoking can contribute to oxidative stress by increasing lipid peroxidation (Solak et al., 2005). However, smoking also induces a potent antioxidant response and increases systemic production of glutathione (Gould et al., 2011). One study found increases in antioxidant enzymes in schizophrenic patients who smoke (Zhang et al., 2007). More data are needed to clarify if smoking contributes to the decreased glutathione in schizophrenia.
Third, the oxidative profile of antipsychotics remains unclear; some studies show antioxidant properties (Parikh et al., 2003, Miljevic et al., 2010, Stojković et al., 2012, Zhang et al., 2012) or improvement of peripheral glutathione and antioxidant enzymes by antipsychotics (Raffa et al., 2009, Zhang et al., 2012). On the other hand, patients on clozapine have shown higher superoxide dismutase and lower glutathione peroxidase, which was interpreted as secondary to increased oxidative stress by clozapine (Miljevic et al., 2010). Hence, we tested if clozapine versus non-clozapine antipsychotics were correlated with glutathione abnormalities in schizophrenia.
Section snippets
Participants
We recruited 54 participants (age range 18–62 years): 29 medicated patients and 25 normal controls, frequency-matched on age, gender and smoking status (Table 1). Patients were recruited from outpatient clinics of Maryland Psychiatric Research Center and neighboring community clinics. Controls were recruited using local media advertisements. Exclusion criteria included major medical and neurological illnesses, history of head injury with cognitive sequelae, mental retardation, substance
GSH and %GSSG levels
Fasting whole blood GSH levels were significantly lower in patients compared with controls (p < 0.001) (Fig. 1A). Fasting GSSG levels were significantly higher in patients vs. controls: patients showed over 5-fold higher in %GSSG compared with controls (p = 0.023) (Fig. 1B). %GSSG in patients also showed large variance: three patients had %GSSG > 50%, largely because they had GSH levels close to zero. The difference remained significant (p = 0.027) even upon removal of these extreme cases: patients
Discussion
This study tested the hypothesis that dietary antioxidant intake, smoking, and antipsychotic medication contribute to abnormal GSH and GSSG levels in schizophrenia. We found no evidence to support the hypothesis that these factors are the primary sources for the abnormal glutathione redox state in patients (Table 2).
Smoking is highly prevalent in schizophrenia (Cooper et al., 2012) although its potential role in the oxidative stress abnormalities in schizophrenia remains unclear. Interestingly,
Role of funding source
Support was received from National Institutes of Health grants R01MH085646, R01DA027680, and R21DA033817.
Contributors
Elliot Hong and Alejandro Ballesteros designed the study. Ann Summerfelt, Pan Jiang and Alejandro Ballesteros collected the data. Elliot Hong and Alejandro Ballesteros managed literature searches and data analyses, and wrote the first draft of the manuscript. All authors contributed to interpretation of results, participated in critical revision of manuscript drafts and approved the final version.
Conflict of interest
All authors report no conflict of interests.
Acknowledgment
There are no further acknowledgements.
References (45)
- et al.
Altered antioxidant defense system in clinically stable patients with schizophrenia and their unaffected siblings
Prog.Neuro-psychopharmacol. Biol. Psychiatry
(2008) - et al.
N-acetyl cysteine as a glutathione precursor for schizophrenia — a double-blind, randomized, placebo-controlled trial
Biol. Psychiatry
(2008) - et al.
Redox dysregulation, neurodevelopment, and schizophrenia
Curr. Opin. Neurobiol.
(2009) - et al.
Consumption of green tea or green tea products: is there an evidence for antioxidant effects from controlled interventional studies?
Phytomedicine
(2011) - et al.
Decreased glutathione levels predict loss of brain volume in children and adolescents with first-episode psychosis in a two-year longitudinal study
Schizophr. Res.
(2012) Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine
Anal. Biochem.
(1980)- et al.
The true oxidized glutathione content of red blood cells obtained by new enzymic and paper chromatographic methods
Anal. Biochem.
(1966) - et al.
Chromatographic and mass spectrometric analysis of glutathione in biological samples
J. Chromatogr. B Anal. Technol. Biomed. Life Sci.
(2009) - et al.
Analysis of glutathione and glutathione disulfide in whole cells and mitochondria by postcolumn derivatization high-performance liquid chromatography with ortho-phthalaldehyde
Anal. Biochem.
(1999) - et al.
Lipid status, antioxidant enzyme defence and haemoglobin content in the blood of long-term clozapine-treated schizophrenic patients
Prog. Neuropsychopharmacol. Biol. Psychiatry
(2010)